Emergent BioSolutions Inc. (EBS) News
Follow Emergent BioSolutions Inc. (EBS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 46 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
EBS Reports Fiscal Q3 2026 Loss
The company reported a loss attributable to shareholders, with basic EPS of -3.99 dollars. Profit fell 292.26% year over year.
EQUITY | Nov 04, 2026, 11:16 AM UTC
L
EBS: trading halted on NYSE — additional information requested (last $6.46)
NYSE halted trading in EBS (additional information requested). Last price $6.46.
EQUITY | Nov 03, 2026, 02:33 PM UTC
M
Emergent BioSolutions Shares Slide as Third-Quarter Revenue Shrinks
Emergent BioSolutions shares fell premarket after the company swung to a third-quarter loss amid a sharp drop in orders from the U.S. government and elsewhere.
EARNINGS | Nov 03, 2026, 01:02 PM UTC
M
Emergent BioSolutions Reports $110M Revenue, $0.64 Loss Per Share
For the 2026 quarter, Emergent BioSolutions reported a $32.7 million net loss, compared with net income of $51.2 million in the prior-year quarter. Revenue was $110 million versus $231.1 million, and diluted loss per sha
EARNINGS | Nov 03, 2026, 11:02 AM UTC
M
Emergent BioSolutions Q3 Earnings Snapshot
EQUITY | Nov 03, 2026, 04:25 AM UTC
M
Emergent BioSolutions Issues FY Adjusted Net Income Outlook
The company’s fiscal-year adjusted net income outlook is stated as USD -10 to 20 million.
EARNINGS | Nov 02, 2026, 10:12 PM UTC
M
Emergent BioSolutions Q3 2026 Earnings Call Begins
Emergent BioSolutions' quarterly earnings call has begun.
EQUITY | Nov 02, 2026, 09:57 PM UTC
M
Emergent BioSolutions Q3 Revenue Falls 52%
Revenue fell 52% on lower NARCAN sales and weaker smallpox product revenue.
EQUITY | Nov 02, 2026, 09:18 PM UTC
M
Emergent BioSolutions Reports Third-Quarter 2026 Financial Results
Emergent BioSolutions reported third-quarter results for the period ended September 30, 2026, including revenue of $110.0 million, in line with its guidance.
EQUITY | Nov 02, 2026, 09:08 PM UTC
L
Emergent BioSolutions Reports 3Q Adjusted Loss Per Share
EARNINGS | Nov 02, 2026, 09:06 PM UTC
M
Erste Raises 2026 Loan and Net Interest Income Outlook
Erste Group raised its 2026 loan volume target to above €290 billion and forecast net interest income growth of more than 6% excluding Poland, up from about 5% previously.
EARNINGS | Oct 30, 2026, 07:52 AM UTC
M
Czech Central Bank Survey Sees Corporate Loan Demand Continuing to Grow
The Czech central bank’s lending survey says demand for corporate loans is expected to continue growing.
RATES | Oct 21, 2026, 08:05 AM UTC
M
Emergent BioSolutions to report Q3 2026 results November 2
The company announced that it will report third-quarter 2026 financial results on November 2, 2026.
EQUITY | Oct 15, 2026, 12:01 PM UTC
M
Vaccine Stocks Rally on Speculation of Contract Awards After Russia Lab Incident
Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advanced after a death at a Russian plague research institute. Retail investors speculated about potential federal contract awa
EQUITY | Oct 06, 2026, 03:34 AM UTC
L
Energy developer Rezolv secures €561 million loan for EU's largest solar park in Romania
Renewable energy developer Rezolv Energy, backed by British sustainable infrastructure investor Actis, said on Wednesday it secured a €561 million ($637 million) green loan from a 14-lender consortium to build the EU’s l
NEWS | Sep 30, 2026, 11:28 AM UTC
L
Erste Group Bank Plans To Launch Tender Offer For About 51% Of Erste Bank Polska Shares At 713.60 Zlotys Each
Erste Group Bank Plans To Launch Tender Offer For About 51% Of Erste Bank Polska Shares At 713.60 Zlotys Each
EQUITY | Sep 28, 2026, 06:38 AM UTC
L
Erste Bank plans offer to raise stake in Erste Bank Polska by up to 26%
Austria's Erste Group Bank VIE:EBS said on Friday it plans to launch a tender offer to take an additional up to 26% stake in Erste Bank Polska GPW:EBP, looking to deepen its exposure to the key Polish market.Erste Group
NEWS | Sep 25, 2026, 07:44 PM UTC
L
Erste Bank plans tender offer for up to 26% more stake in Erste Bank Polska
Erste Group Bank VIE:EBS said on Friday it will launch a tender offer to take another 26% stake in Erste Bank Polska GPW:EBP, up from the 49% it holds currently.The Austrian lender will offer 713 zloty ($185.82) per shar
EQUITY | Sep 25, 2026, 06:43 PM UTC
L
Erste Group: Erste Bank Polska Offer for About PLN713 a Share
Erste Group: Erste Bank Polska Offer for About PLN713 a Share
NEWS | Sep 25, 2026, 06:31 PM UTC
L
Erste Group to Launch Voluntary Tender Offer to Increase Shareholding in Erste Bank Polska >EBS.VI
Erste Group to Launch Voluntary Tender Offer to Increase Shareholding in Erste Bank Polska >EBS.VI
NEWS | Sep 25, 2026, 06:31 PM UTC
L
Erste Group: Offer to Increase Current 49% Shareholding in Erste Bank Polska by Up to Added 26% Stake
Erste Group: Offer to Increase Current 49% Shareholding in Erste Bank Polska by Up to Added 26% Stake
NEWS | Sep 25, 2026, 06:31 PM UTC
L
Erste Group Bank AG (EBS) Plans Tender To Lift EBP Stake Above 50% At ~PLN 713/Share
Erste Group intends a voluntary tender for ~1%—26% of Erste Bank Polska at approx. PLN 713/share to raise its stake above 50% but not over 75%, subject to minimum acceptance, free-float and PFSA approval conditions.Mater
NEWS | Sep 25, 2026, 06:30 PM UTC
L
Erste Group Bank AG (EBS) To Tender For Up To 26% Of Erste Bank Polska
Erste Group plans a voluntary cash tender offer for approx. PLN 713 per EBP share to lift its 49% stake to above 50% and up to 75%, subject to minimum acceptance, free-float and PFSA approval. Launch expected early Nov 2
NEWS | Sep 25, 2026, 06:29 PM UTC
L
PTA-Adhoc: Erste Group Bank AG: Erste Group to launch a voluntary tender offer to increase its shareholding in Erste Bank Polska
Erste Group Bank AGby Thomas Sommerauer/ Simone PilzPublic disclosure of inside information according to article 17 MAR Vienna (pta/25.09.2026/20:05) - Erste Group Bank AG ("Erste Group") announces its intention to launc
NEWS | Sep 25, 2026, 06:28 PM UTC
L
Erste Group to launch a voluntary tender offer to increase its shareholding in Erste Bank Polska
Erste Group Bank AGby Thomas Sommerauer/ Simone PilzPublic disclosure of inside information according to article 17 MARErste Group Bank AG: Erste Group to launch a voluntary tender offer to increase its shareholding in E
MNA | Sep 25, 2026, 06:28 PM UTC
L
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. NYSE:EBS will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its
NEWS | Sep 15, 2026, 11:51 AM UTC
L
EBS - Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
EBS - Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
NEWS | Sep 15, 2026, 11:45 AM UTC
L
Erste Group: He Will Report Directly to CEO Peter Bosek
Erste Group: He Will Report Directly to CEO Peter Bosek
NEWS | Sep 15, 2026, 08:35 AM UTC
L
Erste Group Names Enzersdorfer-Konrad Group Asset Management Executive Director
ERSTE GROUP BANK AG VIE:EBS
NEWS | Sep 15, 2026, 08:35 AM UTC
L
Erste Group: He Will Join Group in 1Q
Erste Group: He Will Join Group in 1Q
NEWS | Sep 15, 2026, 08:35 AM UTC
L
Erste Group: This Is Newly Created Group-Wide Role
Erste Group: This Is Newly Created Group-Wide Role
NEWS | Sep 15, 2026, 08:33 AM UTC
L
Erste Group: Lukas Enzersdorfer-Konrad Appointed Exec Director Asset Management
Erste Group: Lukas Enzersdorfer-Konrad Appointed Exec Director Asset Management
NEWS | Sep 15, 2026, 08:33 AM UTC
L
Bitpanda CEO to go to Austria's Erste Group, kicking off leader search at crypto broker
The CEO of Bitpanda, a Vienna-based broker specialized in crypto assets, is leaving next year to take a role at Austria's Erste Group VIE:EBS, the companies said on Tuesday.
CRYPTO | Sep 15, 2026, 08:30 AM UTC
L
EBS: Strong growth, innovation, and global expansion position the firm as a leader in public health preparedness
The session highlighted a robust portfolio in biodefense and opioid overdose solutions, ongoing transformation for operational efficiency, and strong financial improvements. Growth is driven by international expansion, n
NEWS | Sep 14, 2026, 09:47 PM UTC
L
EBS: Streamlined, debt-reduced, and innovation-focused, the firm leads in global biodefense and public health
A leading provider of medical countermeasures, the firm has streamlined operations, reduced debt, and expanded its global footprint. Key products like NARCAN and new pipeline innovations drive growth, while R&D targets e
NEWS | Sep 14, 2026, 09:33 PM UTC
H
Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance
Emergent BioSolutions presented a business update highlighting Q2 momentum in medical countermeasures, a restructuring delivering ~$40M annualized savings and revised FY2026 guidance.Key Highlights:Original SEC Filing: E
EARNINGS | Sep 14, 2026, 08:04 PM UTC
L
HC Wainwright maintains $10.00/share price target on Emergent Biosolutions
HC Wainwright & Co. maintained a $10.00 per share price target for Emergent Biosolutions, according to a Benzinga ratings action roundup.
EQUITY | Sep 09, 2026, 11:25 AM UTC
L
Emergent BioSolutions completes $75 million note repurchase
Emergent BioSolutions (EBS) completed the repurchase of $75 million aggregate principal amount of senior unsecured notes.
EQUITY | Sep 03, 2026, 11:47 AM UTC
M
Emergent wins $24 million BARDA contract modification
Emergent received a $24 million BARDA contract modification to supply additional doses of CYFENDUS for anthrax preparedness.
REGULATION | Sep 01, 2026, 08:25 PM UTC
M
Emergent BioSolutions gets $24M contract modification for CYFENDUS
Emergent BioSolutions (EBS) was awarded a contract modification valued at approximately $24 million for CYFENDUS®.
EQUITY | Sep 01, 2026, 11:55 AM UTC
L
JPMorgan initiates EBS at Underweight
JPMorgan initiates coverage of EBS with an Underweight rating; no catalyst or price target was supplied in the alert.
EQUITY | Aug 21, 2026, 11:58 AM UTC
L
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions (NYSE: EBS ) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.
EARNINGS | Aug 05, 2026, 08:32 PM UTC
L
EBS - Emergent BioSolutions Reports Second Quarter 2026 Financial Results
EBS - Emergent BioSolutions Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:07 PM UTC
H
White House has added staffers to its pandemic response team amid rising Ebola cases in Africa
Nams Rachel Idowu as Director for Bioresponse at the National Security Council
GEOPOLITICS | Jul 01, 2026, 04:20 PM UTC
H
'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News
'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News
GEOPOLITICS | Jul 01, 2026, 04:19 PM UTC
H
WHO: Ebola Outbreak Outpacing Response
The Ebola outbreak is continuing to outpace the response, according to WHO director Tedros.
EQUITY | Jun 24, 2026, 01:31 PM UTC